ライフサイエンスコーパス: exclusion criteria

1 SE from inception to January 2016 and applied predetermined exclusion criteria.

2 cytes by dependence on the kinase TAK1 and rigorous lineage-exclusion criteria.

3 number of IR patients that do not meet the strict inclusion/exclusion criteria.

4 nth follow-up were included in the study after applying the exclusion criteria.

5 Meta-Analyses guidelines was prepared for the inclusion and exclusion criteria.

6 s were analyzed in detail using predetermined inclusion and exclusion criteria.

7 All consenting patients were included, with no exclusion criteria.

8 es among the subgroup of patients meeting the inclusion and exclusion criteria.

9 antation, or transplantation after 2012 or before 2004 were exclusion criteria.

10 22 studies following PRISMA with pre-defined inclusion and exclusion criteria.

11 ean [SD] age, 65.2 [9.1] years) satisfied the inclusion and exclusion criteria.

12 study who died and underwent autopsy and met inclusion and exclusion criteria.

13 tabase (N = 1172), 128 patients fulfilled the selection and exclusion criteria.

14 from January 1996 to December 2015 that satisfied inclusion/exclusion criteria.

15 les read for full text were screened using an inclusion and exclusion criteria.

16 nd articles were selected based on predefined inclusion and exclusion criteria.

17 screened for suitability and reviewed against inclusion and exclusion criteria.

18 (87% of screening assessments) rather than meeting specific exclusion criteria (52% of screening assessments).

19 After applying appropriate inclusion and exclusion criteria, 56477 patients were included in our analy

20 Discrepancies in inclusion and exclusion criteria and VE estimates were adjudicated by conse

21 otal of 94 patients were enrolled, of whom 44 met inclusion/exclusion criteria and were randomized to the IASD (n=22) and

22 uding median year of conduct, study location, inclusion and exclusion criteria, and study design and quality, was assesse

23 Patients who met the inclusion and exclusion criteria at screening entered a 2-week open-label r

24 ct obstruction (LVOTO) has been traditionally considered an exclusion criteria for AFC.

25 We examined the inclusion and exclusion criteria for each randomized controlled trial and t

26 ictor variables in populations that satisfied inclusion and exclusion criteria for each rule (validation cohort).

27 We used the same inclusion and exclusion criteria for the replication set.

28 We show empirical evidence for exclusion criteria for underperforming probes, providing a so

29 orecards in New York State (NYS) have been studied, but the exclusion criteria have evolved.

30 A screening process, using inclusion/exclusion criteria, identified qualitative studies that focus

31 The exclusion criteria included amblyopia, mental retardation, an

32 Key exclusion criteria included meeting criteria for symptomatic

33 Key exclusion criteria included: CNS involvement, a stroke or int

34 Results Thirty-two studies met inclusion and exclusion criteria, including 3524 imaging examinations: 1963

35 r and publication year, subjects and setting, inclusion and exclusion criteria, mean age and size of the study population

36 REVIEW Using the predetermined inclusion/exclusion criteria, nine reviewers working in pairs assessed

37 ized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might p

38 Of our patients, 7,759 (65.9%) met the inclusion and exclusion criteria of the Canadian Head CT rule, including 11

39 After filtering out compounds based on exclusion criteria, such as toxicity, 36 drugs were retained.

40 Inclusion and exclusion criteria were applied by 2 independent coders with

41 After exclusion criteria were applied, 10 laboratory studies remain

42 admissions (10%) were eligible for analysis once predefined exclusion criteria were applied: 4,804 (31.7%) received "noni

43 Inclusion and exclusion criteria were developed a priori for each question,

44 Given the rarity of patient-matched samples, no exclusion criteria were enacted.

45 Key exclusion criteria were FEV1 less than 70% of predicted value

46 12 individuals who fulfilled the same inclusion and exclusion criteria were included as controls.

47 s AKI stages 1 to 3 (Acute Kidney Injury Network criteria), exclusion criteria were obstructive uropathy, urothelial carc

48 Inclusion and exclusion criteria were specified so that the sample would re

49 Main exclusion criteria were: symptoms for longer than 3 weeks, th

50 individuals with prostate cancer meeting all inclusion and exclusion criteria, with 2,397 (14.2%) receiving ADT during a